|This Slide: #73 of 83|
Slide #73. Acorda Therapeutics, Inc. — Neuronex, Inc.
Acorda Therapeutics, Inc. (NASDAQ:ACOR)
Acorda Therapeutics, Inc. announced that the Company has completed the acquisition of Neuronex, Inc., a privately held company developing a nasal spray formulation of diazepam. Under the terms of the agreement, Acorda paid $6.8 million to Neuronex to complete the acquisition.
Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Co. markets Inbrija (levodopa inhalation powder), which is approved for intermittent treatment of episodic motor fluctuations, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija utilizes Co.'s ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Co. also markets Ampyra (dalfampridine) extended release tablets, 10 mg for improving walking in patients with multiple sclerosis. Ampyra is marketed as Fampyra outside the U.S.
Open the ACOR Page at The Online Investor »
Free ACOR Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Strong Buy (4.00 out of 4)
(ranked higher than approx. 91% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite